

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Gemina Laboratories Ltd. (the "Issuer").

Trading Symbol: GLAB

Number of Outstanding Listed Securities: 73,325,878

Date: June 6, 2023

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The issuer is a biotechnology company that operates in the In Vitro Diagnostics ("IVD") market. The Company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. Gemina's strategy is to focus its efforts on point-of-care diagnostics for respiratory infections conducting research & development, manufacturing,

marketing and distribution activities. The issuer uses third party contractors as required to access expertise, focusing in-house resources on key strategic activities.

Gemina's novel chemistry may have applications beyond the respiratory infections arena with the potential for a wide range of medical and consumer point-of-care tests across a variety of devices. These opportunities will be explored through strategic partnerships.

2. Provide a general overview and discussion of the activities of management.

During the month management was involved in the following activities:

Developing Combination Flu A/B and COVID-19 Rapid Antigen Test.

Product pipeline growth and advancement focused on Flu A/B, TB and Streptococcus diagnostic tests;

Engaging with potential collaborators on extending the issuer's product offering

Investigating and evaluating potential funding alternatives

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products of services developed or offered during the month.

Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the

disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

7. Describe the acquisition of new customers or loss of customers.

None.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

13. Provide details of any securities issued and options or warrants granted.

None

14. Provide details of any loans to or by Related Persons.

None.

15. Provide details of any changes in directors, officers or committee members.

None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Markets for Covid-19 rapid antigen tests is shifting post pandemic, with healthcare providers looking to rapid antigen tests to differentiate between Flu A/B and Covid-19 diagnosis. As a priority, Gemina is advancing a combination Flu A/B and Covid-19 lateral flow test in development.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 6, 2023

Michael Liggett
Name of Director or Senior
Officer

Signed "Michael Liggett"
Signature
CFO _____
Official Capacity

Issuer Details Name of Issuer Gemina Laboratories Ltd.	For Month End May 31, 2023	Date of Report YY/MM/D 23/06/06
Issuer Address 302-3600 Gilmore Way		
City/Province/Postal Code Burnaby, BC, V5G 4R8	Issuer Fax No. ()	Issuer Telephone No. ()
Contact Name Michael Liggett	Contact Position CFO	Contact Telephone No.
Contact Email Address investor@geminalabs.com	Web Site Address geminalabs.com	